Startups attempt to revive exhausted T cells to fight solid tumors, but must strike a balance to avoid triggering adverse events.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers
Journal of Experimental & Clinical Cancer Research Open Access 23 April 2022
-
Promises and challenges of adoptive T-cell therapies for solid tumours
British Journal of Cancer Open Access 29 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Immunotherapy takes aim at exhausted T cells. Nat Biotechnol 38, 3–5 (2020). https://doi.org/10.1038/s41587-019-0381-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0381-y
This article is cited by
-
RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers
Journal of Experimental & Clinical Cancer Research (2022)
-
Promises and challenges of adoptive T-cell therapies for solid tumours
British Journal of Cancer (2021)